论文部分内容阅读
儿童哮喘大多是过敏性哮喘,特异性免疫治疗是目前惟一针对过敏性疾病的对因治疗,和对症治疗相辅相成,最终达到治愈过敏性疾病的目的。舌下特异性免疫治疗(SLIT)是近年来提倡的针对过敏性哮喘的新疗法。SLIT确切的作用机制仍不清楚,国内外研究证实SLIT对儿童哮喘安全有效,无严重不良事件发生,依从性较好,能预防新的过敏症发生。SLIT可能提供机制填补目前过敏症实验的空白。
Most childhood asthma is allergic asthma, specific immunotherapy is currently the only treatment for allergic diseases, and symptomatic treatment complement each other, and ultimately achieve the purpose of healing allergic diseases. Sublingual immunotherapy (SLIT) is a new therapy advocated in recent years for allergic asthma. The exact mechanism of action of SLIT remains unclear. Studies at home and abroad confirm that SLIT is safe and effective for children with asthma, without serious adverse events and with good compliance, and can prevent new allergies. SLIT may provide a mechanism to fill gaps in current allergy experiments.